Mitsubishi Tanabe looks for HIT with UK launch of danaparoid rival argatroban
This article was originally published in Scrip
Mitsubishi Tanabe Pharma's (MTP) European subsidiary has launched the direct thrombin inhibitor Exembol (argatroban) in the UK for the treatment of adult patients with heparin-induced thrombocytopenia type II (HIT) who require parenteral antithrombotic therapy.
You may also be interested in...
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.
While Xtandi has positive new survival data in prostate cancer, other rivals in the competitive market are reporting the same at ASCO.
Join Scrip and the Pink Sheet’s Asia content team for a wide-ranging look at the ongoing multiple impacts of the pandemic on the pharma industry.